MedPath

Effects of Vitamin D Supplementation on Obesity, Inflammatory and Metabolic Markers

Not Applicable
Completed
Conditions
Overweight
Hypovitaminosis D
Interventions
Dietary Supplement: Vitamin D supplement
Registration Number
NCT05376865
Lead Sponsor
Tirang R. Neyestani, Ph.D.
Brief Summary

46 eligible overweight women with hypovitaminosis D are assigned to either vitamin D or control group using block randomization method. Vitamin D3 pearl (Zahravi Pharma Co, Tabriz, Iran) containing 50000 IU cholecalciferol or placebo are administered weekly for 12 weeks. Participants in both groups are structured to hold their sun exposure and physical activity habits and not take any vitamin supplements during the study.

Detailed Description

For the randomized controlled clinical trial (RCT), the first fifty eligible women were assigned to either the vitamin D or placebo group using the block randomization method. Each Vitamin D3 pearl (Zahravi Pharma Co, Tabriz, Iran) contained 50000 IU cholecalciferol and was administered weekly for 12 weeks according to guidelines for treating vitamin D deficiency. Placebo pearls (Zahravi Pharma Co, Tabriz, Iran) had the identical appearance, taste, and smell as the vitamin D pearls and could only be identified by the package code. The placebo pearls were administered similarly. To keep the study double-blinded, an assistant who was not involved in assessments managed the randomization and supplement assignment procedure. Participants were structured to hold their sun exposure and physical activity habits and not take any vitamin supplements during the study. They were also asked to inform the researcher before taking any new medications. All participants were provided with a moderately reduced diet (a reduction of 300 kcal per day) based on their basal weight. The nutrigenetic study investigated 75 eligible women (including the vitamin D group and the last fifty women who entered the study). The nutrigenetic study protocol was the same as that mentioned above for the vitamin D group in the RCT. Compliance was ensured by weekly text messages and voice calls to remind the users of the supplement on the given day. In addition, the supplement and placebo pearls were presented in two visits; once at the baseline visit and then after six weeks. Pearls packs were collected from each subject (at week 6 and week 12) to check if all the pearls were consumed as recommended.

During the first and last visits, anthropometric and laboratory assessments were performed for all subjects. The primary outcomes are improving anthropometric, inflammatory, and metabolic markers of overweight women with hypovitaminosis D.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
46
Inclusion Criteria
  • low serum vitamin D level <30ng/ml
  • 25<BMI<30 kg/m2
  • Age: 20-50
  • Free of chronic diseased such as cancer, diabetes, cardiovascular disease, renal diseases, gastrointestinal diseases, no multivitamin supplement intake, no change in weight in the last 3 months
Exclusion Criteria
  • Getting pregnant during the study
  • Suffering from thyroid disorders and other diseases mentioned during the study
  • Not taking supplements weekly

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
InterventionVitamin D supplementVitamin D3 supplement every week
ControlVitamin D supplementPlacebo every week
Primary Outcome Measures
NameTimeMethod
Serum 25(OH)D12 weeks

Fasting serum 25-hydroxyvitamin D level

Weight12 weeks

Subject's weight wearing light clothing

Secondary Outcome Measures
NameTimeMethod
Serum triglyceride12 weeks

Fasting serum triglyceride level Fasting serum triglyceride leve

Serum hsCRP12 weeks

Fasting serum high sensitivity c-reactive protein level

Serum IL-612 weeks

Fasting serum Interleukin-6 level

Serum total cholesterol12 weeks

Fasting serum total cholesterol level

Fat mass12 weeks

Total body fat mass measured by Bioelectrical Impedance analysis method

Serum Fasting Glucose12 weeks

Fasting serum glucose level

Serum TNF-a12 weeks

Fasting serum tumor necrosis factor alpha level

Serum PTH12 weeks

Fasting serum parathyroid hormone level

Waist circumference12 weeks

the measurement at the midpoint between the lowest rib and the iliac crest

Trial Locations

Locations (1)

Laboratory of Nutrition Research, National Nutrition and Food Technology Research Institute (NNFTRI) and Faculty of Nutrition Science and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran

🇮🇷

Tehran, Iran, Islamic Republic of

© Copyright 2025. All Rights Reserved by MedPath